Volta Labs, a genomics applications company, today announced the launch of its Library Prep App for Oxford Nanopore LSK114 on the Callisto™ Sample Prep System. This latest addition to the growing Volt ...

Pacific Biosciences of California (PACB) ended the recent trading session at $1.18, demonstrating a +1.72% change from the ...

A research team has identified two novel genetic mechanisms for disease resistance in wheat, offering promising strategies to ...

Genomics company Pacific Biosciences of California (NASDAQ:PACB) announced better-than-expected revenue in Q1 CY2025, but ...

PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset sales cycle delays and drive 2025 growth.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Pacific Biosciences of California faces steep stock decline and financial challenges. Click here to see why PACB stock is a ...

The use of cutting-edge genomic tools and technologies, including DNA sequencing, molecular markers, and bioinformatics, empowers researchers to accelerate the breeding process, reduce breeding cycles ...

MENLO PARK, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly ...

Non-GAAP net loss per share for the first quarter of 2025 was $0.15 compared to $0.26 for the first quarter of 2024. Updates since PacBio's last earnings release Initiated a company-wide restructuring ...

PacBio reported Q1 2025 revenue of $37.2 million, a decrease from $38.8 million in Q1 2024, amid restructuring efforts. PacBio reported its financial results for the first quarter of 2025 ...